MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/pharmaceutics18070881

Медицинская библиотека · Pharmaceutics · 2026

Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer.

Wang Junbiao, Lamolinara Alessia, Tomassoni Daniele, Conti Laura, Cossu Chiara, Di Lorenzo Antonino, Giangrossi Mara, Lufrano Daniela, Vaithianathan Varshini, Orlando Fiorenza, Olivieri Fabiola, Marcozzi Serena, Beghelli Daniela, Belletti Barbara, Amici Augusto, Falconi Maurizio, Cavallo Federica, Iezzi Manuela, Marchini Cristina

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

Cancer vaccines represent the next frontier in immunotherapy, aiming to elicit long-lasting protective anti-tumor immune responses. Human epidermal growth factor receptor 2 (HER2) is a well-established therapeutic target in breast cancer. Active immunization with HER2-displaying M13 bacteriophages can induce a therapeutic immune response against HER2-positive breast cancer, offering a promising alternative to trastuzumab. However, the duration of anticancer immune protection triggered by anti-HER2 phage-based vaccines is limited by tumor-immune suppressive mechanisms.

Methods

In this study, two vaccination cycles with ECTM phages displaying the extracellular (EC) and transmembrane (TM) domains of human HER2 were combined with palbociclib, a CDK4/6 inhibitor, to enhance antitumor immunity in the clinically relevant Δ16HER2 transgenic preclinical model of breast cancer.

Results

The proposed combination treatment resulted in a better and long-lasting control of tumor growth rate and multiplicity than either palbociclib or phage vaccination alone, correlating with a significantly stronger anti-HER2 humoral response (IgG2a isotype). Analysis of the tumor immune infiltrate revealed an increased presence of CD8+ T cells concomitant with a reduction in FoxP3+ regulatory T cells (Tregs) in tumors explanted from mice receiving the combination therapy.

Conclusions

These preclinical results provide a rationale for the clinical translation of CDK4/6 inhibitors combined with anti-HER2 active immunotherapies in breast cancer, as they may yield sustained antitumor responses by reverting the immunosuppressive tumor environment.

Для цитирования: Wang Junbiao, Lamolinara Alessia, Tomassoni Daniele, Conti Laura, Cossu Chiara, Di Lorenzo Antonino, Giangrossi Mara, Lufrano Daniela, Vaithianathan Varshini, Orlando Fiorenza, Olivieri Fabiola, Marcozzi Serena, Beghelli Daniela, Belletti Barbara, Amici Augusto, Falconi Maurizio, Cavallo Federica, Iezzi Manuela, Marchini Cristina. Targeting CDK4/6 in Combination with Phage-Based Anti-HER2 Vaccination Overcomes Immune Evasion and Enhances the Anticancer Response in Breast Cancer.. Pharmaceutics. 2026. DOI: 10.3390/pharmaceutics18070881.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.